A multicenter, open-label phase II trial of a new customized dosing (Rational Adjustment of Dose to reduce Adverse Reactions RADAR” dosing) of niraparib as maintenance therapy in platinum sensitive ovarian, fallopian tube or primary peritoneal recurrent cancer patients. - NEWTO

Istituto di Ricerche Farmacologiche Mario Negri IRCCS0 个研究点目标入组 105 人开始时间: 2020年2月20日最近更新: 2022年3月2日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 105

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: Female

入选标准

•1.18 years of age or older, female, any race
•2.Histologically diagnosed ovarian cancer, fallopian tube cancer or primary peritoneal cancer
•3.High grade (or grade 3) serous histology or known to have gBRCAmut
•4.Has received at least 2 previous lines of platinum-containing therapy (not necessarily consecutive), and has disease that was considered platinum sensitive following the penultimate platinum line (more than 6-months period between penultimate platinum regimen and progression of disease)
•5.Has responded to the last platinum line (PR or CR)
•6.No more than 8 weeks have elapsed from completion of the last platinum regimen and the patient is still not progressing after response
•7.Eastern Cooperative Oncology Group (ECOG) performance status of = 1
•8.Adequate bone marrow, kidney and liver function, defined as follows:
•a.Absolute neutrophil count = 1,500/µL
•b.Platelets = 100,000/µL
•c.Hemoglobin = 9 g/dL
•d.Serum creatinine = 1.5 x upper limit of normal (ULN) or calculated creatinine clearance = 30 mL/min using the Cockcroft-Gault equation
•e.Total bilirubin = 1.5 x ULN (=2.0 in patients with known Gilberts syndrome) OR direct bilirubin = 1 x ULN
•f.Aspartate aminotransferase and alanine aminotransferase = 2.5 x ULN unless liver metastases are present, in which case they must be = 5 x ULN
•9.Patient receiving corticosteroids may continue as long as their dose is stable for least 4 weeks prior to initiating protocol therapy.
•10.Patient must have a negative urine or serum pregnancy test within 7 days
•prior to taking study treatment if childbearing potential and agrees to abstain
•from activities that could result in pregnancy from screening through 180
•days after the last dose of study treatment or use highly effective
•contraception throughout the study. Such methods include: combined
•(estrogen and progestogen containing) hormonal contraception associated
•with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-
•only hormonal contraception associated with inhibition of ovulation (oral,
•injectable, implantable), intrauterine device (IUD), intrauterine hormone-
•releasing system (IUS), bilateral tubal occlusion, vasectomized partner. In
•case of vomiting and diarrhea patient should use an additional barrier
•method. Non-childbearing potential is defined as follows (by other than
•medical reasons): =45 years of age and has not had menses for >1 year;
•patients with amenorrhea for <2 years without history of a hysterectomy and
•oophorectomy must have a follicle stimulating hormone value in the
•postmenopausal range upon screening evaluation; Post-hysterectomy, post-
•bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or
•oophorectomy must be confirmed with medical records of the actual
•procedure or confirmed by an ultrasound. Tubal ligation must be confirmed
•with medical records, otherwise the patient must be willing to use highly
•effective contraception throughout the study, starting with the screening
•visit through 180 days after the last dose of study treatment.
•11.Patient must agree to not breastfeed during the study and for 180 days after the last dose of study treatment.
•12.Patient must be able to understand the study procedures and agree to participate in the study by providing written informed consent.
•13. Patients must have normal blood pressure or adequately treated and controlled hypertension. (i.e. systolic BP = 140 mmHg and diatolic BP = 90 mmHg)
•Are the trial subjects under 18? no

排除标准

•1.Patient simultaneously enrolled in any interventional clinical trial
•2.Invasive cancer other than ovarian cancer within 2 years (except basal or squamous cell carcinoma of the skin that has been definitely treated)
•3.Patient with known, symptomatic brain or leptomeningeal metastases
•4.Patient with immunocompromised status
•5.Patient with known active hepatic disease
•6.Prior treatment with a known PARP inhibitor
•7.Patient who has had major surgery = 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects.
•8.Patient who has received investigational therapy = 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior initiating protocol therapy.
•9.Patient has had radiation therapy encompassing >20% of the bone marrow within 2 weeks prior to day 1 of protocol therapy
•10.Patient has had any radiation therapy within 1 week prior to day 1 of protocol therapy.
•11.Patient with known hypersensitivity to niraparib components or excipients.
•12.Patient has received a transfusion (platelets or red blood cells) = 4 weeks prior to initiating protocol therapy.
•13.Patient has received colony stimulating factors (e.g., granulocyte colony-stimulating factor, granulocyte macrophage colony stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy.
•14.Patient has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment.
•15.Patient with any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
•16.Patient with a serious, uncontrolled medical disorder. Examples include, but are not limited to, nonmalignant systemic disease, active, uncontrolled infection, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent
•17. Patient who might be dependent on the sponsor, CRO, site or the
•investigator.
•18. Patient who has been incarcerated or involuntarily institutionalized
•by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG

研究者

发起方

Istituto di Ricerche Farmacologiche Mario Negri IRCCS

相似试验

未知

2 期

A phase II study, multicenter, open label trial of R1415 (erlotinib hydrochloride) in patients with advanced/metastatic or recurrent non-small cell lung cancer. (JO18396)Advanced or metastatic or recurrent non-small cell lung cancer

JPRN-jRCT2080220075Chugai Pharmaceutical Co., Ltd.

未知

2 期

A phase 2 study, multicenter, open label trial of R1415 (erlotinib hydrochloride) in patients with advanced, metastatic or recurrent non-small cell lung cancer.(JO16565)Advanced or metastatic or recurrent non-small cell lung cancer

JPRN-jRCT2080220076Chugai Pharmaceutical Co., Ltd.

进行中（未招募）

1 期

Study of safety and efficacy of INC280 alone, and in combination with erlotinib, compared to chemotherapy, in advanced/metastatic non-small cell lung cancer patients with EGFR mutation and cMET amplificatioon-small cell lung cancerMedDRA version: 18.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-001241-84-GBovartis Pharma Services AG23

进行中（未招募）

1 期

EUCTR2015-001241-84-FRovartis Pharma Services AG23

进行中（未招募）

1 期

Study of safety and efficacy of INC280 alone, and in combination with erlotinib, compared to chemotherapy, in advanced/metastatic non-small cell lung cancer patients with EGFR mutation and cMET amplificatioon-small cell lung cancerMedDRA version: 19.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-001241-84-PTovartis Pharma Services AG135